Myron S Cohen 1 , Ying Q Chen 1 , Marybeth McCauley 1 , Theresa Gamble 1 , Mina C Hosseinipour 1 , Nagalingeswaran Kumarasamy 1 , James G Hakim 1 , Johnstone Kumwenda 1 , Beatriz Grinsztejn 1 , Jose H S Pilotto 1 , Sheela V Godbole 1 , Suwat Chariyalertsak 1 , Breno R Santos 1 , Kenneth H Mayer 1 , Irving F Hoffman 1 , Susan H Eshleman 1 , Estelle Piwowar-Manning 1 , Leslie Cottle 1 , Xinyi C Zhang 1 , Joseph Makhema 1 , Lisa A Mills 1 , Ravindre Panchia 1 , Sharlaa Faesen 1 , Joseph Eron 1 , Joel Gallant 1 , Diane Havlir 1 , Susan Swindells 1 , Vanessa Elharrar 1 , David Burns 1 , Taha E Taha 1 , Karin Nielsen-Saines 1 , David D Celentano 1 , Max Essex 1 , Sarah E Hudelson 1 , Andrew D Redd 1 , Thomas R Fleming 1
Sep 01 2016
An interim analysis of data from the HIV Prevention Trials Network (HPTN) 052 trial showed that antiretroviral therapy (ART) prevented more than 96% of genetically linked infections caused by human immunodeficiency virus type 1 (HIV-1) in serodiscordant couples. ART was then offered to all patients with HIV-1 infection (index participants). The study included more than 5 years of follow-up to assess the durability of such therapy for the prevention of HIV-1 transmission.